Ocuphire Pharma Analyst Ratings
Ocuphire Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 555.74% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 08/14/2023 | 457.38% | Cantor Fitzgerald | → $17 | Reiterates | Overweight → Overweight |
| 08/14/2023 | 555.74% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 05/16/2023 | 555.74% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 03/31/2023 | 555.74% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 02/17/2023 | 555.74% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 01/26/2023 | 555.74% | HC Wainwright & Co. | $26 → $20 | Maintains | Buy |
| 11/24/2021 | 752.46% | HC Wainwright & Co. | → $26 | Initiates Coverage On | → Buy |
| 04/05/2021 | 719.67% | Alliance Global Partners | → $25 | Initiates Coverage On | → Buy |
| 03/29/2021 | 555.74% | JonesTrading | → $20 | Initiates Coverage On | → Buy |
| 03/15/2021 | 555.74% | Cantor Fitzgerald | $15 → $20 | Maintains | Overweight |
| 02/10/2021 | 621.31% | Canaccord Genuity | → $22 | Initiates Coverage On | → Buy |
| 11/20/2020 | 391.8% | Cantor Fitzgerald | → $15 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/14/2023 | 555.74% | HC Wainwright & Co. | → 20 美元 | 重申 | 购买 → 购买 |
| 08/14/2023 | 457.38% | 坎托·菲茨杰拉德 | → 17 美元 | 重申 | 超重 → 超重 |
| 08/14/2023 | 555.74% | HC Wainwright & Co. | → 20 美元 | 重申 | 购买 → 购买 |
| 05/16/2023 | 555.74% | HC Wainwright & Co. | → 20 美元 | 重申 | 购买 → 购买 |
| 03/31/2023 | 555.74% | HC Wainwright & Co. | → 20 美元 | 重申 | → 购买 |
| 02/17/2023 | 555.74% | HC Wainwright & Co. | → 20 美元 | 重申 | → 购买 |
| 01/26/2023 | 555.74% | HC Wainwright & Co. | 26 美元 → 20 美元 | 维护 | 买 |
| 11/24/2021 | 752.46% | HC Wainwright & Co. | → 26 美元 | 启动覆盖范围开启 | → 购买 |
| 04/05/2021 | 719.67% | 联盟全球合作伙伴 | → 25 美元 | 启动覆盖范围开启 | → 购买 |
| 03/29/2021 | 555.74% | JonesTrading | → 20 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 3 月 15 日 | 555.74% | 坎托·菲茨杰拉德 | 15 美元 → 20 美元 | 维护 | 超重 |
| 2021 年 10 月 2 日 | 621.31% | Canaccord Genu | → 22 美元 | 启动覆盖范围开启 | → 购买 |
| 11/20/2020 | 391.8% | 坎托·菲茨杰拉德 | → 15 美元 | 启动覆盖范围开启 | → 超重 |
What is the target price for Ocuphire Pharma (OCUP)?
Ocuphire Pharma（OCUP）的目标价格是多少？
The latest price target for Ocuphire Pharma (NASDAQ: OCUP) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $20.00 expecting OCUP to rise to within 12 months (a possible 555.74% upside). 7 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月14日公布了Ocuphire Pharma（纳斯达克股票代码：OCUP）的最新目标股价。该分析公司将目标股价定为20.00美元，预计OCUP将在12个月内升至12个月内（可能上涨555.74％）。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Ocuphire Pharma (OCUP)?
分析师对Ocuphire Pharma（OCUP）的最新评级是多少？
The latest analyst rating for Ocuphire Pharma (NASDAQ: OCUP) was provided by HC Wainwright & Co., and Ocuphire Pharma reiterated their buy rating.
Ocuphire Pharma（纳斯达克股票代码：OCUP）的最新分析师评级由HC Wainwright & Co. 提供，Ocuphire Pharma重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Ocuphire Pharma (OCUP)?
Ocuphire Pharma（OCUP）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ocuphire Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ocuphire Pharma was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Ocuphire Pharma的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Ocuphire Pharma的最新评级是在2023年11月14日公布的，因此您应该预计下一个评级将在2024年11月14日左右公布。
Is the Analyst Rating Ocuphire Pharma (OCUP) correct?
分析师对Ocuphire Pharma（OCUP）的评级正确吗？
While ratings are subjective and will change, the latest Ocuphire Pharma (OCUP) rating was a reiterated with a price target of $0.00 to $20.00. The current price Ocuphire Pharma (OCUP) is trading at is $3.05, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但重申了最新的Ocuphire Pharma（OCUP）评级，目标股价为0.00美元至20.00美元。Ocuphire Pharma（OCUP）目前的交易价格为3.05美元，在分析师的预测区间内。